BPC 157 dosage

Every published BPC 157 dosage figure, from the 6–50 μg/kg used in rodent studies to the 200–500 mcg daily protocols cited in peptide literature and the 10–20 mg IV infusion tested in the 2025 human pilot. Pharmacokinetics, reconstitution math, and how dosing actually translates across species.

The standard BPC 157 dosage in research

BPC 157 dosage in the peer-reviewed literature spans a much wider range than most summary articles suggest, because the drug has been studied across species and administration routes. In rodent models — where the bulk of the published data lives — the most common range is 6–50 micrograms per kilogram body weight (μg/kg), administered once or twice daily via intraperitoneal, intramuscular, subcutaneous, intravenous, or oral routes. For a 300-gram rat, 10 μg/kg translates to just 3 micrograms per dose.

Scaling these rodent doses to humans is not straightforward because pharmacokinetics, tissue distribution, and receptor sensitivity differ across species. The peptide literature and the protocols referenced in peptide-user communities typically cluster around 200–500 micrograms subcutaneous per day in humans — administered once or twice daily. The 250 mcg and 500 mcg figures are the most frequently cited.

This human dosing range is not derived from a formal human dose-ranging study. Almost no such study exists in the published literature. The numbers come from a combination of allometric scaling from rodent data, practical dosing patterns at compounding pharmacies during the years BPC 157 was being prepared under §503A, and community protocols accumulated on peptide forums.

BPC 157 half-life and pharmacokinetics

BPC 157 has a short elimination half-life. Following intramuscular or intravenous administration, the peptide is cleared from circulation with a half-life of less than 30 minutes. This short duration is characteristic of small peptides, which are rapidly cleared by renal filtration and proteolytic degradation. The short half-life is the primary pharmacokinetic justification for daily — sometimes twice-daily — dosing rather than weekly depot dosing.

The pharmacokinetic picture for oral BPC 157 is less clear. Body Protection Compound's parent molecule originates from gastric juice, which has led to claims that BPC 157 is unusually stable in the acidic environment of the stomach compared to most peptides. Some preclinical work supports this resistance to gastric degradation, but systemic bioavailability after oral administration has not been rigorously characterized in humans. What is clear is that animal studies demonstrating efficacy by oral route typically use doses an order of magnitude higher than the equivalent subcutaneous doses — consistent with reduced but non-zero absorption.

BPC 157 dosage chart by vial size

BPC 157 is typically supplied in 5 mg or 10 mg lyophilized vials, reconstituted with bacteriostatic water before injection. The table below shows how each vial size maps to common subcutaneous dosing targets and how long a vial lasts at each dose.

Units on the chart assume a standard U-100 insulin syringe, where 1.00 mL equals 100 units. Reconstitution volume changes the injection volume but not the delivered dose. A larger diluent volume makes small doses easier to measure accurately; a smaller diluent volume means less liquid to inject. The peptide content per dose is determined only by the vial strength and the target amount in micrograms.

BPC 157 dosing schedule

The three standard scheduling considerations in BPC 157 protocols are frequency, timing, and duration.

• Frequency. Daily dosing is the norm, aligned with the short half-life. Some protocols split the total daily dose into two injections — morning and evening — though there is no clinical trial data showing this produces better outcomes than once-daily dosing.
• Timing relative to injury site. When BPC 157 is used for a localized injury, injections are sometimes administered near the affected area rather than at a generic subcutaneous site. This is based on the rationale that local tissue concentrations may matter more than systemic levels. The supporting data for this approach is anecdotal; no head-to-head human trials compare local versus systemic injection.
• Duration. Most protocols cited in peptide literature run for 4 to 8 weeks of continuous daily dosing, with the option to extend based on observed results. There is no clinical evidence that cycling BPC 157 is necessary, but there is also no long-term safety data beyond a few weeks of continuous dosing in humans.

Oral BPC 157 dosage versus injection

Oral BPC 157 — sold as capsules, troches, tablets, arginate salt formulations, and sublingual lozenges — is attractive because it avoids needles. Research and peptide communities have spent significant effort characterizing whether oral dosing actually works, and the honest answer is that it produces some effect but at much higher doses than injection.

Animal studies showing oral BPC 157 efficacy typically use doses 5–10 times higher than the equivalent injectable dose to achieve comparable biological effects. Translated to human protocols, that puts oral BPC 157 dosing in the range of 1–5 mg per day — an order of magnitude higher than the 250–500 mcg used in subcutaneous protocols. Practical oral formulations often contain 250–500 mcg per capsule and are dosed 2–4 times daily.

BPC 157 dosage calculator logic

If you are reviewing a vial and working out the correct injection volume, the math is:

Injection volume (mL) = target dose (mcg) ÷ (vial amount in mcg ÷ reconstitution volume in mL)

A worked example: a 10 mg vial (10,000 mcg) reconstituted with 2 mL of bacteriostatic water has a concentration of 5,000 mcg/mL. To deliver a 250 mcg dose, you draw 250 ÷ 5,000 = 0.05 mL — 5 units on a U-100 insulin syringe. For a 500 mcg dose, double to 0.10 mL (10 units).

The 2025 IV infusion pilot study

In 2025, a small pilot study in two adult humans examined intravenous BPC 157 at what would be considered aggressive doses by any standard: 10 mg infused on day one, followed by 20 mg the following day. The study measured a full panel of safety biomarkers — cardiac, hepatic, renal, thyroid, and glucose — and reported no adverse effects at either dose. Both participants tolerated the infusion.

This study is important context for understanding BPC 157's apparent tolerability at large doses, but it is not a basis for recommending IV infusion protocols. Two participants is too small to characterize safety, the study was not placebo-controlled, and no long-term follow-up has been published. The relevant takeaway is that BPC 157 does not appear to cause acute toxicity at doses far exceeding subcutaneous research protocols — which is consistent with the broader pattern of reported tolerability in the literature.

Frequently asked questions